January 28, 2015
A Manhattan federal judge on Tuesday threw out an investor class action and a related securities fraud damages suit against Sanofi over a 2013 setback in its effort alongside recently acquired Genzyme Corp. to win approval for their Lemtrada multiple sclerosis drug, finding rosy statements predicting on-time approval were genuinely believed when they were made.
April 04, 2014
Sanofi SA and its top executives allegedly misled investors about the potential success of its subsidiary's multiple sclerosis drug Lemtrada, causing shareholders to miss out on millions of dollars when the drug failed to receive regulatory approval, a complaint filed in New York federal court claims.